Literature DB >> 8367814

Reduction of systemic drug exposure after hepatic arterial infusion of doxorubicin with complete hepatic venous isolation and extracorporeal chemofiltration.

S A Curley1, D R Byrd, R A Newman, H J Ellis, J Chase, C H Carrasco, K Cleary, W Bodden, D C Hohn.   

Abstract

BACKGROUND: Hepatic arterial infusion of doxorubicin has produced tumor response in hepatic malignancies; however, the limited success of these treatments is related in part to dose-limiting systemic toxicities. The purpose of this study was to determine whether a novel venous isolation-chemofiltration system could limit systemic exposure to doxorubicin after hepatic arterial infusion.
METHODS: Doxorubicin (1 or 3 mg/kg) was infused in the hepatic arteries of domestic pigs after complete hepatic venous isolation was achieved with a dual-balloon vena cava catheter. The hepatic vein effluent was pumped through an extracorporeal carbon chemofiltration circuit. Doxorubicin levels were measured in prefilter (hepatic vein), postfilter, and systemic serum at intervals up to 1 hour after drug infusion.
RESULTS: Complete hepatic venous isolation with extracorporeal chemofiltration significantly reduced (> 90%) the postfilter and systemic levels of doxorubicin compared with prefilter levels (p < 0.01). At the time animals were killed 7 days after infusion of doxorubicin (3 mg/kg), tissue levels of doxorubicin in the liver showed a 16-fold increase compared with levels in the heart (p < 0.01).
CONCLUSIONS: For chemotherapeutic drugs like doxorubicin with a low first-pass extraction by the liver, the novel system described herein achieved significant reduction in systemic drug exposure. This system will allow dose intensification of doxorubicin administered by hepatic arterial infusion to treat hepatic malignancies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8367814

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies.

Authors:  James F Pingpank; Steven K Libutti; Richard Chang; Bradford J Wood; Ziv Neeman; Anthony W Kam; William D Figg; Souping Zhai; Tatiana Beresneva; Geoffrey D Seidel; H Richard Alexander
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

2.  In vitro clearance of doxorubicin with a DNA-based filtration device designed for intravascular use with intra-arterial chemotherapy.

Authors:  Mariam S Aboian; Jay F Yu; Ayushi Gautam; Chia-Hung Sze; Jeffrey K Yang; Jonathan Chan; Prasheel V Lillaney; Caroline D Jordan; Hee-Jeung Oh; David M Wilson; Anand S Patel; Mark W Wilson; Steven W Hetts
Journal:  Biomed Microdevices       Date:  2016-12       Impact factor: 2.838

3.  Optimization of an endovascular magnetic filter for maximized capture of magnetic nanoparticles.

Authors:  Sravani Kondapavulur; Andre M Cote; Kiel D Neumann; Caroline D Jordan; David McCoy; Marc C Mabray; Derek Liu; Chia-Hung Sze; Ayushi Gautam; Henry F VanBrocklin; Mark Wilson; Steven W Hetts
Journal:  Biomed Microdevices       Date:  2016-12       Impact factor: 2.838

4.  Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: a phase I study.

Authors:  S A Curley; R A Newman; T B Dougherty; G M Fuhrman; D L Stone; J A Mikolajek; S Guercio; A Guercio; C H Carrasco; M T Kuo
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

5.  Increased doxorubicin levels in hepatic tumors with reduced systemic drug exposure achieved with complete hepatic venous isolation and extracorporeal chemofiltration.

Authors:  S A Curley; D L Stone; G M Fuhrman; D C Hohn; Z H Siddik; R A Newman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  In Vitro Capture of Small Ferrous Particles with a Magnetic Filtration Device Designed for Intravascular Use with Intraarterial Chemotherapy: Proof-of-Concept Study.

Authors:  Marc C Mabray; Prasheel Lillaney; Chia-Hung Sze; Aaron D Losey; Jeffrey Yang; Sravani Kondapavulur; Derek Liu; Maythem Saeed; Anand Patel; Daniel Cooke; Young-Wook Jun; Ivan El-Sayed; Mark Wilson; Steven W Hetts
Journal:  J Vasc Interv Radiol       Date:  2015-12-22       Impact factor: 3.464

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.